US FDA To Exercise ‘Maximum Regulatory Flexibility’ For COVID-19 Plasma-Derived Therapeutics

 
• By Sue Sutter
  
Coronavirus 2019-nCoV Blood Sample. Corona virus outbreaking. Epidemic virus Respiratory Syndrome. China
Industry is seeking plasma donations from individuals who have recovered from COVID-19. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D